Reimbursement Framework for Biosimilars
Created on February 24, 2017
In this program, Stephanie Trunk, a health care partner at Arent Fox LLP in Washington, DC will examine the reimbursement framework that surrounds biosimilars. Stephanie counsels pharmaceutical and device manufacturers, distributors, and their customers, including pharmacy benefit managers, on regulatory, reimbursement, and compliance matters.
A biosimilar product is a biological product that is approved based on a showing that it is highly similar to an FDA-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. Attendees will learn about how biosimilars are currently treated and reimbursed under various programs, including:
- Medicare Part B
- Part D
- Qualified Health Plans sold on Exchanges
- Various commercial plans
The program will also discuss potential changes to biosimilar reimbursement under the new Administration.
- Gain an understanding of biosimilar products
- Learn how biosimilars are currently reimbursed under various programs
- Discuss potential changes to biosimilar reimbursement under the Trump Administration
Gain access to this course, plus unlimited access to 1,500+ courses, with an Unlimited Subscription.Explore Lawline Subscriptions